History

Astellas launched Geninax^®, an oral new-type quinololone antibacterial agent, in Japan.

Astellas launched Betanis^® in Japan for the treatment of overactive bladder (OAB).

Astellas launched a wind turbine power generation station and a woodchip biomass boiler in the Kerry Plant in Ireland.

Astellas launched Gonax^® in Japan for the treatment of prostate cancer.

Astellas and Amgen concluded an agreement for established alliance innovative joint venture, Astellas Amgen Biopharma in Japan.

Astellas launched Suglat^® in Japan for the treatment of type 2 diabetes.

Astellas launched XTANDI^® in Japan for the treatment of prostate cancer.

Astellas acquired Ocata Therapeutics, Inc., a biotechnology company in the U.S. to enable Astellas to establish a presence in ophthalmology and a leading position in cell theapy.

Astellas launched Repatha^® in Japan for the treatment of high cholesterol.

Astellas acquired Ganymed Pharmaceticals AG, a biopharmaceutical company, in Germany to further expand Astellas' oncology presence by adding anti-body program, zolbetuximab.

Astellas participated in Access Accelerated, a global initiative aimed at improving access to non-communicable diseases prevention, diagonosis and treatment.

Astellas launched LINZESS^® in Japan for the treatment of irritable bowel syndrome with conspitation.

Astellas acquired Ogeda SA, a drug discovery company, in Belgium to expand Astellas' pipeline by adding a selective NK3 receptor atagonist, fezolinetant.

Astellas acquired Mitobridge, Inc., a bio-venture company in the U.S. to accelerate Astellas' research and development in diseases associated with mitochondrial dysfunctions.

Astellas acquired Universal Cells, Inc., a bio-venture company which has ability to produce pluripotent stem cells that have lower immunological rejections.

Astellas acquired Quethera, a gene theraphy company in the U.K. to further Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma.

Astellas launched Dafclir^® in Japan for the treatment of infectious enteritis caused by Clostridium difficile.

Astellas launched BLINCYTO^® in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.

Astellas launched XOSPATA^® in Japan and the U.S. to provide a therapeutic option for the treatment of Acute Myeloid Leukemia.

Astellas acquired Potenza Therapeutics Inc. in the U.S. to add clinical stage novel immuno-oncology programs to Astellas' oncology pipeline.

Astellas launched EVENITY^® in Japan for the treatment of osteoporosis.

Astellas launched Evrenzo^® in Japan for the treatment of renal anemia in patients on dialysis.

Astellas acquired Xyphos Biosciences, Inc., a biotechnology company in the U.S. to accelerate next-generation cancer immunotherapy.

Astellas acquired Audentes Therapeutics, Inc., a biotechnology company in the U.S. to complement capabilities and resources of Astellas for creating an industry-leading gene therapy company.

Astellas acquired Nanna Therapeutics Limited, in the U.K. to accelerate Astellas' research in diseases associated with mitochondrial dysfunctions.